|
|
|
|
 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
[2010]
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
February 3, 2010
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer |
January 29, 2010
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom’s Macroglobulinemia |
January 25, 2010
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer |
January 22, 2010
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price |
January 21, 2010
Æterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastrointestinal Cancers Symposium |
 |
 |
|
|
|
